NCT01511536 - Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions

Prostate Cancer

Interventions

DRUG

Cabazitaxel XRP6258

Pharmaceutical form:solution Route of administration: injection

DRUG

Abiraterone acetate

Pharmaceutical form:tablets Route of administration: oral

DRUG

Prednisone 5 mg

Route of administration: oral

Trial Locations (4)

Investigational Site Number 250001, Villejuif

Investigational Site Number 840001, San Francisco

Investigational Site Number 840002, New Haven

Investigational Site Number 826001, Sutton